CALGARY – August 24, 2012 – XORTX Pharma Corp. today announced the formation of a privately held Pharmaceutical Development Company built upon novel patents (intellectual property) in the fields of hypertension, insulin resistance, metabolic syndrome and diabetes prevention.
The novel patents protect the use of all uric acid lowering agents (approved and in development) for the treatment of the aforementioned disease entities. Recent discoveries show that chronically increased, serum uric acid plays a modulating role in the development of early onset hypertension, insulin resistance and diabetes. Strong, scientifically rigorous animal and human data supports the patent applications. Most importantly, a phase II pilot study in adolescents with hypertension, showed that modest doses of uric acid lowering agents can normalize blood pressure andblock weight gain in a clinically meaningful, statistically significant way (Feig D, Soletsky B, Johnson RJ. Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential Hypertension: A Randomized Trial. JAMA 2008;300(8):924-932).
About XORTX Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies that will improve patient health throughout the world. XORTX Pharma Corp. has one primary program focused on the treatment of hypertension in adolescents with accompanying hyperuricemia. Secondary programs include uric acid lowering agents to treat insulin resistance and a diagnostic for detection of susceptibility to dermal rash and Stevens-Johnson Syndrome.
XORTX Pharma Corp. is a privately held company. For more information, please visit our web site at www.xortx.com.
Forward-Looking Statement Disclaimer
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Risks, uncertainties and factors that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks, uncertainties and factors related to the fact that: we, together with our collaborative partners, may not be able to successfully develop all or any of our current or future products and may not be able to obtain regulatory approval in targeted indications for our current or future products in all markets; we may not achieve or maintain profitability; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital as and when required; we depend on our collaborative partners to perform their obligations under licensing or other collaborative agreements; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; any of our products that obtain regulatory approval will be subject to extensive post-market regulation that may affect sales, marketing and profitability; any of our products that are successfully developed may not achieve market acceptance; we rely on third parties for the continued supply and manufacture of our products and have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters, including with respect to our ability to protect our intellectual property; we face increased competition from pharmaceutical and biotechnology companies; and other. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.